INTRODUCTION
Osteoporosis (OP) is a progressive skeletal disease involving low bone mineral density (BMD) that often affects the aged population, especially postmenopausal women, and potentially leads to fragility fracture.1 To maintain proper strength and integrity, bone undergoes constant turnover that is controlled by a balance between osteoclast-maintained bone resorption (osteoclastogenesis) and osteoblast-induced bone formation (osteoblastogenesis).2 OP is a result when osteoclastogenesis exceeds osteoblastogenesis and is histomorpho-logically characterized by reduced BMD and trabecular microstruc-ture deterioration. The pathogenesis of OP involves various endogenous and exogenous factors, including aging, weight-related mechanical stimulation, abnormal mineral and hormone metabolism, and stresses of various natures that are mechanistically linked to the altered transcription of osteogenic genes. Recent studies have shown that abnormal epigenetic modification partici-pates in the control of osteoclastogenesis and osteoblastogenesis.3–4 In particular, DNA methylation profiling investigations detect many genomic loci/genes that are modified by DNA methylation altera-tions in the trabeculae of patients with OP,5–6 identifying another fundamental mechanism of the pathogenesis of OP.